

TITLE OF THE INVENTION

4-RING IMIDAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5

5 BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention is directed to imidazole compounds substituted with i) a heteroaryl ring and ii) another heteroaryl or aryl ring with at least one of the rings being further substituted with another ring. In particular, this invention is directed to imidazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, which are metabotropic glutamate receptor – subtype 5 (“mGluR5”) modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, bipolar disorder, and circadian rhythm disorders, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.

RELATED BACKGROUND

20 A major excitatory neurotransmitter in the mammalian nervous system is the glutamate molecule, which binds to neurons, thereby activating cell surface receptors. Such surface receptors are characterized as either ionotropic or metabotropic glutamate receptors. The metabotropic glutamate receptors (“mGluR”) are G protein-coupled receptors that activate intracellular second messenger systems when bound to glutamate. Activation of mGluR results in a variety of cellular responses. In particular, mGluR1 and mGluR5 activate phospholipase C, which is followed by mobilizing intracellular calcium.

Modulation of metabotropic glutamate receptor subtype 5 (mGluR5) is useful in the treatment of diseases that affect the nervous system (see for example W.P.J.M Spooren et al., *Trends Pharmacol. Sci.*, 22:331-337 (2001) and references cited therein). For example, recent 30 evidence demonstrates the involvement of mGluR5 in nociceptive processes and that modulation of mGluR5 using mGluR5-selective compounds is useful in the treatment of various pain states, including acute, persistent and chronic pain [K Walker et al., *Neuropharmacology*, 40:1-9 (2001); F. Bordi, A. Ugolini *Brain Res.*, 871:223-233 (2001)], inflammatory pain [K Walker et al., *Neuropharmacology*, 40:10-19 (2001); Bhave et al. *Nature Neurosci.* 4:417-423 (2001)] and 35 neuropathic pain [Dogru et al. *Neurosci. Lett.* 292:115-118 (2000)].

Further evidence supports the use of modulators of mGluR5 in the treatment of psychiatric and neurological disorders. For example, mGluR5-selective compounds such as 2-methyl-6-(phenylethynyl)-pyridine ("MPEP") are effective in animal models of mood disorders, including anxiety and depression [W.P.J.M Spooren et al., *J. Pharmacol. Exp. Ther.*, 295:1267-1275 (2000); E. Tatarczynska et al, *Brit. J. Pharmacol.*, 132:1423-1430 (2001); A. Kłodzynska et al, *Pol. J. Pharmacol.*, 132:1423-1430 (2001)]. Gene expression data from humans indicate that modulation of mGluR5 may be useful for the treatment of schizophrenia [T. Ohnuma et al, *Mol. Brain. Res.*, 56:207-217 (1998); *ibid*, *Mol. Brain. Res.*, 85:24-31 (2000)]. Studies have also shown a role for mGluR5, and the potential utility of mGluR5-modulatory compounds, in the treatment of movement disorders such as Parkinson's disease [W.P.J.M Spooren et al., *Europ. J. Pharmacol.* 406:403-410 (2000); H. Awad et al., *J. Neurosci.* 20:7871-7879 (2000); K. Ossawa et al. *Neuropharmacol.* 41:413-420 (2001)]. Other research supports a role for mGluR5 modulation in the treatment of cognitive dysfunction [G. Riedel et al, *Neuropharmacol.* 39:1943-1951 (2000)], epilepsy [A. Chapman et al, *Neuropharmacol.* 39:1567-1574 (2000)] and 15 neuroprotection [V. Bruno et al, *Neuropharmacol.* 39:2223-2230 (2000)]. Studies with mGluR5 knockout mice and MPEP also suggest that modulation of these receptors may be useful in the treatment of drug addiction, drug abuse and drug withdrawal [C. Chiamulera et al. *Nature Neurosci.* 4:873-874 (2001)].

International Patent Publications WO 01/12627 and WO 99/26927 describe 20 heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists.


U.S. Patent No. 3,647,809 describes pyridyl-1,2,4-oxadiazole derivatives. U.S. Patent No. 4,022,901 describes 3-pyridyl-5-isothiocyanophenyl oxadiazoles. International Patent Publication WO 98/17652 describes oxadiazoles, WO 97/03967 describes various substituted aromatic compounds, JP 13233767A and WO 94/22846 describe various heterocyclic 25 compounds.

Compounds that include ringed systems are described by various investigators as effective for a variety of therapies and utilities. For example, International Patent Publication No. WO 98/25883 describes ketobenzamides as calpain inhibitors, European Patent Publication No. EP 811610 and U.S. Patent Nos. 5,679,712, 5,693,672 and 5,747,541 describe substituted 30 benzoylguanidine sodium channel blockers, and U.S. Patent No. 5,736,297 describes ring systems useful as a photosensitive composition.

However, there remains a need for novel compounds and compositions that therapeutically inhibit mGluR5 with minimal side effects.

35 SUMMARY OF THE INVENTION

The present invention is directed to novel imidazole compounds such as those of Formula (I):




(I)

5 (where A, B, R₁₁, R₁₂, W, X, Y and Z are as defined herein) wherein the imidazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, which are metabotropic glutamate receptor –
 10 subtype 5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders – such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. This invention also provides a pharmaceutical composition which includes an effective amount of the novel imidazole
 15 compounds substituted with a heteroaryl moiety, and a pharmaceutically acceptable carrier.

This invention further provides a method of treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, bipolar disorders, and circadian rhythm and sleep disorders, as well as a method of treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, obesity, drug addiction, drug abuse and drug withdrawal
 20 by the administration of an effective amount of the novel imidazole compounds substituted with a heteroaryl moiety.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention are represented by Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

X and Y each independently is aryl or heteroaryl wherein at least one of X and Y is a heteroaryl with N adjacent to the position of attachment to A or B respectively;

5 X is optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein 10 the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

15 R¹, R², and R³ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

20 R⁴ is -C₁-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

25 A is -C₀-4alkyl, -C₀-2alkyl-SO-C₀-2alkyl-, -C₀-2alkyl-SO₂-C₀-2alkyl-, -C₀-2alkyl-CO-C₀-2alkyl-, -C₀-2alkyl-NR⁹CO-C₀-2alkyl-, -C₀-2alkyl-NR⁹SO₂-C₀-2alkyl- or -heteroC₀-4alkyl;

30 W is -C₃-7cycloalkyl, -heteroC₃-7cycloalkyl, -C₀-6alkylaryl, or -C₀-6alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

35 Y is optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl),

—O(aryl), —N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or —N(C₀-6alkyl)(aryl) groups;

R⁵, R⁶, and R⁷ each independently is —C₀-6alkyl, —C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, —CN, —C₁-6alkyl, —

5 O(C₀-6alkyl), —O(C₃-7cycloalkyl), —O(aryl), —N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), —N(C₀-6alkyl)(aryl) substituents;

R⁸ is —C₁-6alkyl, —C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, —CN, —C₁-6alkyl, —O(C₀-6alkyl), —O(C₃-7cycloalkyl), —O(aryl), —N(C₀-6alkyl)(C₀-6alkyl), —N(C₀-6alkyl)(C₃-7cycloalkyl), —N(C₀-6alkyl)(aryl) substituents;

10 B is —C₀-4alkyl, —C₀-2alkyl—SO—C₀-2alkyl—, —C₀-2alkyl—SO₂—C₀-2alkyl—, —C₀-2alkyl—CO—C₀-2alkyl—, —C₀-2alkyl—NR¹⁰CO—C₀-2alkyl—, —C₀-2alkyl—NR¹⁰SO₂—C₀-2alkyl— or —heteroC₀-4alkyl;

R⁹ and R¹⁰ each independently is —C₀-6alkyl, —C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, —CN, —C₁-6alkyl, —

15 O(C₀-6alkyl), —O(C₃-7cycloalkyl), —O(aryl), —N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), —N(C₀-6alkyl)(aryl) substituents;

Z is —C₃-7cycloalkyl, —heteroC₃-7cycloalkyl, —C₀-6alkylaryl, or —C₀-6alkylheteroaryl optionally substituted with 1-7 independent halogen, —CN, NO₂, —C₁-6alkyl, —C₁-6alkenyl, —C₁-6alkynyl, —OR¹, —NR¹R², —C(=NR¹)NR²R³, —N(=NR¹)NR²R³, —

20 NR¹COR², —NR¹CO₂R², —NR¹SO₂R⁴, —NR¹CONR²R³, —SR⁴, —SOR⁴, —SO₂R⁴, —SO₂NR¹R², —COR¹, —CO₂R¹, —CONR¹R², —C(=NR¹)R², or —C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

R¹¹ and R¹² is each independently halogen, —C₀-6alkyl, —C₀-6alkoxyl, =O, =N(C₀-4alkyl), or —N(C₀-4alkyl)(C₀-4alkyl);

25 any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

In one aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

X is 2-pyridyl optionally substituted with 1-4 independent halogen, —CN, NO₂,

30 —C₁-6alkyl, —C₁-6alkenyl, —C₁-6alkynyl, —OR¹, —NR¹R², —C(=NR¹)NR²R³, —N(=NR¹)NR²R³, —NR¹COR², —NR¹CO₂R², —NR¹SO₂R⁴, —NR¹CONR²R³, —SR⁴, —SOR⁴, —SO₂R⁴, —SO₂NR¹R², —COR¹, —CO₂R¹, —CONR¹R², —C(=NR¹)R², or —C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the —C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, —CN, —C₁-6alkyl, —O(C₀-6alkyl), —O(C₃-7cycloalkyl),

–O(aryl), –N(C₀–6alkyl)(C₀–6alkyl), –N(C₀–6alkyl)(C₃–7cycloalkyl), or –N(C₀–6alkyl)(aryl) groups;

R¹, R², and R³ each independently is –C₀–6alkyl, –C₃–7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1–5 independent halogen, –CN, –C₁–6alkyl, –

5 O(C₀–6alkyl), –O(C₃–7cycloalkyl), –O(aryl), –N(C₀–6alkyl)(C₀–6alkyl), –N(C₀–6alkyl)(C₃–7cycloalkyl), –N(C₀–6alkyl)(aryl) substituents;

R⁴ is –C₁–6alkyl, –C₃–7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1–5 independent halogen, –CN, –C₁–6alkyl, –O(C₀–6alkyl), –O(C₃–7cycloalkyl), –O(aryl), –N(C₀–6alkyl)(C₀–6alkyl), –N(C₀–6alkyl)(C₃–7cycloalkyl), –N(C₀–6alkyl)(aryl) substituents;

10 A is –C₀–4alkyl, –C₀–2alkyl–SO–C₀–2alkyl–, –C₀–2alkyl–SO₂–C₀–2alkyl–, –C₀–2alkyl–CO–C₀–2alkyl–, –C₀–2alkyl–NR⁹CO–C₀–2alkyl–, –C₀–2alkyl–NR⁹SO₂–C₀–2alkyl– or –heteroC₀–4alkyl;

15 W is –C₃–7cycloalkyl, –heteroC₃–7cycloalkyl, –C₀–6alkylaryl, or –C₀–6alkylheteroaryl optionally substituted with 1–7 independent halogen, –CN, NO₂, –C₁–6alkyl, –C₁–6alkenyl, –C₁–6alkynyl, –OR¹, –NR¹R², –C(=NR¹)NR²R³, –N(=NR¹)NR²R³, –NR¹COR², –NR¹CO₂R², –NR¹SO₂R⁴, –NR¹CONR²R³, –SR⁴, –SOR⁴, –SO₂R⁴, –SO₂NR¹R², –COR¹, –CO₂R¹, –CONR¹R², –C(=NR¹)R², or –C(=NOR¹)R² substituents;

20 Y is aryl or heteroaryl optionally substituted with 1–7 independent halogen, –CN, NO₂, –C₁–6alkyl, –C₁–6alkenyl, –C₁–6alkynyl, –OR⁵, –NR⁵R⁶, –C(=NR⁵)NR⁶R⁷, –N(=NR⁵)NR⁶R⁷, –NR⁵COR⁶, –NR⁵CO₂R⁶, –NR⁵SO₂R⁸, –NR⁵CONR⁶R⁷, –SR⁸, –SOR⁸, –SO₂R⁸, –SO₂NR⁵R⁶, –COR⁵, –CO₂R⁵, –CONR⁵R⁶, –C(=NR⁵)R⁶, or –C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the –C₁–6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1–5 independent halogen, –CN, –C₁–6alkyl, –O(C₀–6alkyl), –O(C₃–7cycloalkyl), –O(aryl), –N(C₀–6alkyl)(C₀–6alkyl), –N(C₀–6alkyl)(C₃–7cycloalkyl), or –N(C₀–6alkyl)(aryl) groups;

25 30 R⁵, R⁶, and R⁷ each independently is –C₀–6alkyl, –C₃–7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1–5 independent halogen, –CN, –C₁–6alkyl, –O(C₀–6alkyl), –O(C₃–7cycloalkyl), –O(aryl), –N(C₀–6alkyl)(C₀–6alkyl), –N(C₀–6alkyl)(C₃–7cycloalkyl), –N(C₀–6alkyl)(aryl) substituents;

R⁸ is –C₁–6alkyl, –C₃–7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1–5 independent halogen, –CN, –C₁–6alkyl, –O(C₀–6alkyl), –O(C₃–7cycloalkyl), –O(aryl), –N(C₀–6alkyl)(C₀–6alkyl), –N(C₀–6alkyl)(C₃–7cycloalkyl), –N(C₀–6alkyl)(aryl) substituents;

B is $-C_0-4alkyl$, $-C_0-2alkyl-SO-C_0-2alkyl$, $-C_0-2alkyl-SO_2-C_0-2alkyl$, $-C_0-2alkyl-CO-C_0-2alkyl$, $-C_0-2alkyl-NR^{10}CO-C_0-2alkyl$, $-C_0-2alkyl-NR^{10}SO_2-C_0-2alkyl$ or $-heteroC_0-4alkyl$;

5 R⁹ and R¹⁰ each independently is $-C_0-6alkyl$, $-C_3-7cycloalkyl$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

10 Z is $-C_3-7cycloalkyl$, $-heteroC_3-7cycloalkyl$, $-C_0-6alkylaryl$, or $-C_0-6alkylheteroaryl$ optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

15 R¹¹ and R¹² is each independently halogen, -C₀-6alkyl, -C₀-6alkoxyl, =O, =N(C₀-4alkyl), or -N(C₀-4alkyl)(C₀-4alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

In an embodiment of this one aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

20 X is 2-pyridyl optionally substituted with 1-4 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

30 R¹, R², and R³ each independently is $-C_0-6alkyl$, $-C_3-7cycloalkyl$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

35 R⁴ is $-C_1-6alkyl$, $-C_3-7cycloalkyl$, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

A is $-C_0\text{-}4\text{alkyl}$, $-C_0\text{-}2\text{alkyl}-SO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-SO_2-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^9CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^9SO_2-C_0\text{-}2\text{alkyl}-$ or $-heteroC_0\text{-}4\text{alkyl}$;

W is $-C_3\text{-}7\text{cycloalkyl}$, $-heteroC_3\text{-}7\text{cycloalkyl}$, $-C_0\text{-}6\text{alkylaryl}$, or $-C_0$.

5 6alkylheteroaryl optionally substituted with 1-7 independent halogen, $-CN$, NO_2 , $-C_1\text{-}6\text{alkyl}$, $-C_1\text{-}6\text{alkenyl}$, $-C_1\text{-}6\text{alkynyl}$, $-OR^1$, $-NR^1R^2$, $-C(=NR^1)NR^2R^3$, $-N(=NR^1)NR^2R^3$, $-NR^1COR^2$, $-NR^1CO_2R^2$, $-NR^1SO_2R^4$, $-NR^1CONR^2R^3$, $-SR^4$, $-SOR^4$, $-SO_2R^4$, $-SO_2NR^1R^2$, $-COR^1$, $-CO_2R^1$, $-CONR^1R^2$, $-C(=NR^1)R^2$, or $-C(=NOR^1)R^2$ substituents;

10 Y is phenyl optionally substituted with 1-5 independent halogen, $-CN$, NO_2 , $-C_1\text{-}6\text{alkyl}$, $-C_1\text{-}6\text{alkenyl}$, $-C_1\text{-}6\text{alkynyl}$, $-OR^5$, $-NR^5R^6$, $-C(=NR^5)NR^6R^7$, $-N(=NR^5)NR^6R^7$, $-NR^5COR^6$, $-NR^5CO_2R^6$, $-NR^5SO_2R^8$, $-NR^5CONR^6R^7$, $-SR^8$, $-SOR^8$, $-SO_2R^8$, $-SO_2NR^5R^6$, $-COR^5$, $-CO_2R^5$, $-CONR^5R^6$, $-C(=NR^5)R^6$, or $-C(=NOR^5)R^6$ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the $-C_1\text{-}6\text{alkyl}$ substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, $-CN$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(aryl)$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, or $-N(C_0\text{-}6\text{alkyl})(aryl)$ groups;

15 R⁵, R⁶, and R⁷ each independently is $-C_0\text{-}6\text{alkyl}$, $-C_3\text{-}7\text{cycloalkyl}$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(aryl)$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(aryl)$ substituents;

20 R⁸ is $-C_1\text{-}6\text{alkyl}$, $-C_3\text{-}7\text{cycloalkyl}$, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, $-CN$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(aryl)$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(aryl)$ substituents;

25 B is $-C_0\text{-}4\text{alkyl}$, $-C_0\text{-}2\text{alkyl}-SO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-SO_2-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^{10}CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^{10}SO_2-C_0\text{-}2\text{alkyl}-$ or $-heteroC_0\text{-}4\text{alkyl}$;

30 R⁹ and R¹⁰ each independently is $-C_0\text{-}6\text{alkyl}$, $-C_3\text{-}7\text{cycloalkyl}$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(aryl)$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(aryl)$ substituents;

Z is $-C_3\text{-}7\text{cycloalkyl}$, $-heteroC_3\text{-}7\text{cycloalkyl}$, $-C_0\text{-}6\text{alkylaryl}$, or $-C_0$. 6alkylheteroaryl optionally substituted with 1-7 independent halogen, $-CN$, NO_2 , $-C_1\text{-}6\text{alkyl}$, $-C_1\text{-}6\text{alkenyl}$, $-C_1\text{-}6\text{alkynyl}$, $-OR^1$, $-NR^1R^2$, $-C(=NR^1)NR^2R^3$, $-N(=NR^1)NR^2R^3$, $-$

NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

R¹¹ and R¹² is each independently halogen, -C₀₋₆alkyl, -C₀₋₆alkoxyl, =O,

5 =N(C₀₋₄alkyl), or -N(C₀₋₄alkyl)(C₀₋₄alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

10 In a second aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

X is aryl or heteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -

15 SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups;

20 R¹, R², and R³ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

25 R⁴ is -C₁₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

30 A is -C₀₋₄alkyl, -C₀₋₂alkyl-SO-C₀₋₂alkyl-, -C₀₋₂alkyl-SO₂-C₀₋₂alkyl-, -C₀₋₂alkyl-CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR⁹CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR⁹SO₂-C₀₋₂alkyl- or -heteroC₀₋₄alkyl;

35 W is -C₃₋₇cycloalkyl, -heteroC₃₋₇cycloalkyl, -C₀₋₆alkylaryl, or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

Y is 2-pyridyl optionally substituted with 1-4 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally

5 two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups;

10 R⁵, R⁶, and R⁷ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

15 R⁸ is -C₁₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

B is -C₀₋₄alkyl, -C₀₋₂alkyl-SO-C₀₋₂alkyl-, -C₀₋₂alkyl-SO₂-C₀₋₂alkyl-, -C₀₋₂alkyl-CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR¹⁰CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR¹⁰SO₂-C₀₋₂alkyl- or -heteroC₀₋₄alkyl;

20 R⁹ and R¹⁰ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

25 Z is -C₃₋₇cycloalkyl, -heteroC₃₋₇cycloalkyl, -C₀₋₆alkylaryl, or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

30 R¹¹ and R¹² is each independently halogen, -C₀₋₆alkyl, -C₀₋₆alkoxyl, =O, =N(C₀₋₄alkyl), or -N(C₀₋₄alkyl)(C₀₋₄alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

35 In an embodiment of this second aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

X is phenyl optionally substituted with 1-5 independent halogen, -CN, NO₂, -C₁-alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally

5 two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

10 R¹, R², and R³ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

15 R⁴ is -C₁-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

A is -C₀-4alkyl, -C₀-2alkyl-SO-C₀-2alkyl-, -C₀-2alkyl-SO₂-C₀-2alkyl-, -C₀-2alkyl-CO-C₀-2alkyl-, -C₀-2alkyl-NR⁹CO-C₀-2alkyl-, -C₀-2alkyl-NR⁹SO₂-C₀-2alkyl- or -heteroC₀-4alkyl;

20 W is -C₃-7cycloalkyl, -heteroC₃-7cycloalkyl, -C₀-6alkylaryl, or -C₀-6alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

25 Y is 2-pyridyl optionally substituted with 1-4 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein

30 the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

35 R⁵, R⁶, and R⁷ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -

O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

R⁸ is -C₁-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

5 B is -C₀-4alkyl, -C₀-2alkyl-SO-C₀-2alkyl-, -C₀-2alkyl-SO₂-C₀-2alkyl-, -C₀-2alkyl-CO-C₀-2alkyl-, -C₀-2alkyl-NR¹⁰CO-C₀-2alkyl-, -C₀-2alkyl-NR¹⁰SO₂-C₀-2alkyl- or -heteroC₀-4alkyl;

10 R⁹ and R¹⁰ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

15 Z is -C₃-7cycloalkyl, -heteroC₃-7cycloalkyl, -C₀-6alkylaryl, or -C₀-6alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

20 R¹¹ and R¹² is each independently halogen, -C₀-6alkyl, -C₀-6alkoxyl, =O, =N(C₀-4alkyl), or -N(C₀-4alkyl)(C₀-4alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

In a third aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

25 X is phenyl optionally substituted with 1-5 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

35 R¹, R², and R³ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -

$O(C_{0-6}alkyl)$, $-O(C_{3-7}cycloalkyl)$, $-O(aryl)$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-N(C_{0-6}alkyl)(C_{3-7}cycloalkyl)$, $-N(C_{0-6}alkyl)(aryl)$ substituents;

R^4 is $-C_{1-6}alkyl$, $-C_{3-7}cycloalkyl$, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, $-CN$, $-C_{1-6}alkyl$, $-O(C_{0-6}alkyl)$, $-O(C_{3-7}cycloalkyl)$, $-O(aryl)$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-N(C_{0-6}alkyl)(C_{3-7}cycloalkyl)$, $-N(C_{0-6}alkyl)(aryl)$ substituents;

A is $-C_{0-4}alkyl$, $-C_{0-2}alkyl-SO-C_{0-2}alkyl-$, $-C_{0-2}alkyl-SO_2-C_{0-2}alkyl-$, $-C_{0-2}alkyl-CO-C_{0-2}alkyl-$, $-C_{0-2}alkyl-NR^9CO-C_{0-2}alkyl-$, $-C_{0-2}alkyl-NR^9SO_2-C_{0-2}alkyl-$ or $-heteroC_{0-4}alkyl$;

W is $-C_{3-7}cycloalkyl$, $-heteroC_{3-7}cycloalkyl$, $-C_{0-6}alkylaryl$, or $-C_{0-6}alkylheteroaryl$ optionally substituted with 1-7 independent halogen, $-CN$, NO_2 , $-C_{1-6}alkyl$,

$-C_{1-6}alkenyl$, $-C_{1-6}alkynyl$, $-OR^1$, $-NR^1R^2$, $-C(=NR^1)NR^2R^3$, $-N(=NR^1)NR^2R^3$, $-NR^1COR^2$, $-NR^1CO_2R^2$, $-NR^1SO_2R^4$, $-NR^1CONR^2R^3$, $-SR^4$, $-SOR^4$, $-SO_2R^4$, $-SO_2NR^1R^2$, $-COR^1$, $-CO_2R^1$, $-CONR^1R^2$, $-C(=NR^1)R^2$, or $-C(=NOR^1)R^2$ substituents;

Y is aryl or heteroaryl optionally substituted with 1-7 independent halogen, $-CN$, NO_2 , $-C_{1-6}alkyl$, $-C_{1-6}alkenyl$, $-C_{1-6}alkynyl$, $-OR^5$, $-NR^5R^6$, $-C(=NR^5)NR^6R^7$, $-N(=NR^5)NR^6R^7$, $-NR^5COR^6$, $-NR^5CO_2R^6$, $-NR^5SO_2R^8$, $-NR^5CONR^6R^7$, $-SR^8$, $-SOR^8$, $-SO_2R^8$, $-SO_2NR^5R^6$, $-COR^5$, $-CO_2R^5$, $-CONR^5R^6$, $-C(=NR^5)R^6$, or $-C(=NOR^5)R^6$ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y ; wherein the $-C_{1-6}alkyl$ substituent, cycloalkyl ring, or

$heterocycloalkyl$ ring each optionally is further substituted with 1-5 independent halogen, $-CN$, $-C_{1-6}alkyl$, $-O(C_{0-6}alkyl)$, $-O(C_{3-7}cycloalkyl)$, $-O(aryl)$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-N(C_{0-6}alkyl)(C_{3-7}cycloalkyl)$, or $-N(C_{0-6}alkyl)(aryl)$ groups;

R^5 , R^6 , and R^7 each independently is $-C_{0-6}alkyl$, $-C_{3-7}cycloalkyl$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, $-C_{1-6}alkyl$,

$O(C_{0-6}alkyl)$, $-O(C_{3-7}cycloalkyl)$, $-O(aryl)$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-N(C_{0-6}alkyl)(C_{3-7}cycloalkyl)$, $-N(C_{0-6}alkyl)(aryl)$ substituents;

R^8 is $-C_{1-6}alkyl$, $-C_{3-7}cycloalkyl$, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, $-CN$, $-C_{1-6}alkyl$, $-O(C_{0-6}alkyl)$, $-O(C_{3-7}cycloalkyl)$, $-O(aryl)$, $-N(C_{0-6}alkyl)(C_{0-6}alkyl)$, $-N(C_{0-6}alkyl)(C_{3-7}cycloalkyl)$, $-N(C_{0-6}alkyl)(aryl)$ substituents;

B is $-C_{0-4}alkyl$, $-C_{0-2}alkyl-SO-C_{0-2}alkyl-$, $-C_{0-2}alkyl-SO_2-C_{0-2}alkyl-$, $-C_{0-2}alkyl-CO-C_{0-2}alkyl-$, $-C_{0-2}alkyl-NR^{10}CO-C_{0-2}alkyl-$, $-C_{0-2}alkyl-NR^{10}SO_2-C_{0-2}alkyl-$ or $-heteroC_{0-4}alkyl$;

R^9 and R^{10} each independently is $-C_{0-6}alkyl$, $-C_{3-7}cycloalkyl$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, $-C_{1-6}alkyl$,

$O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(\text{aryl})$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(\text{aryl})$ substituents;

5 Z is $-C_3\text{-}7\text{cycloalkyl}$, $-\text{hetero}C_3\text{-}7\text{cycloalkyl}$, $-C_0\text{-}6\text{alkylaryl}$, or $-C_0\text{-}6\text{alkylheteroaryl}$ optionally substituted with 1-7 independent halogen, $-\text{CN}$, NO_2 , $-C_1\text{-}6\text{alkyl}$, $-C_1\text{-}6\text{alkenyl}$, $-C_1\text{-}6\text{alkynyl}$, $-OR^1$, $-NR^1R^2$, $-C(=NR^1)NR^2R^3$, $-N(=NR^1)NR^2R^3$, $-NR^1COR^2$, $-NR^1CO_2R^2$, $-NR^1SO_2R^4$, $-NR^1CONR^2R^3$, $-SR^4$, $-SOR^4$, $-SO_2R^4$, $-SO_2NR^1R^2$, $-COR^1$, $-CO_2R^1$, $-CONR^1R^2$, $-C(=NR^1)R^2$, or $-C(=NOR^1)R^2$ substituents;

10 one of W and Z is optionally absent;

10 R¹¹ and R¹² is each independently halogen, $-C_0\text{-}6\text{alkyl}$, $-C_0\text{-}6\text{alkoxyl}$, $=O$, $=N(C_0\text{-}4\text{alkyl})$, or $-N(C_0\text{-}4\text{alkyl})(C_0\text{-}4\text{alkyl})$; and

15 any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

In a fourth aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

15 X is aryl or heteroaryl optionally substituted with 1-7 independent halogen, $-\text{CN}$, NO_2 , $-C_1\text{-}6\text{alkyl}$, $-C_1\text{-}6\text{alkenyl}$, $-C_1\text{-}6\text{alkynyl}$, $-OR^1$, $-NR^1R^2$, $-C(=NR^1)NR^2R^3$, $-N(=NR^1)NR^2R^3$, $-NR^1COR^2$, $-NR^1CO_2R^2$, $-NR^1SO_2R^4$, $-NR^1CONR^2R^3$, $-SR^4$, $-SOR^4$, $-SO_2R^4$, $-SO_2NR^1R^2$, $-COR^1$, $-CO_2R^1$, $-CONR^1R^2$, $-C(=NR^1)R^2$, or $-C(=NOR^1)R^2$ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the $-C_1\text{-}6\text{alkyl}$ substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, $-\text{CN}$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(\text{aryl})$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, or $-N(C_0\text{-}6\text{alkyl})(\text{aryl})$ groups;

25 R¹, R², and R³ each independently is $-C_0\text{-}6\text{alkyl}$, $-C_3\text{-}7\text{cycloalkyl}$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, $-\text{CN}$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(\text{aryl})$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(\text{aryl})$ substituents;

30 R⁴ is $-C_1\text{-}6\text{alkyl}$, $-C_3\text{-}7\text{cycloalkyl}$, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, $-\text{CN}$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(\text{aryl})$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(\text{aryl})$ substituents;

35 A is $-C_0\text{-}4\text{alkyl}$, $-C_0\text{-}2\text{alkyl}-SO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-SO_2-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^9CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^9SO_2-C_0\text{-}2\text{alkyl}-$ or $-\text{hetero}C_0\text{-}4\text{alkyl}$;

40 W is $-C_3\text{-}7\text{cycloalkyl}$, $-\text{hetero}C_3\text{-}7\text{cycloalkyl}$, $-C_0\text{-}6\text{alkylaryl}$, or $-C_0\text{-}6\text{alkylheteroaryl}$ optionally substituted with 1-7 independent halogen, $-\text{CN}$, NO_2 , $-C_1\text{-}6\text{alkyl}$,

-C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

5 Y is phenyl optionally substituted with 1-5 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further 10 substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

15 R⁵, R⁶, and R⁷ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

20 R⁸ is -C₁-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

B is -C₀-4alkyl, -C₀-2alkyl-SO-C₀-2alkyl-, -C₀-2alkyl-SO₂-C₀-2alkyl-, -C₀-2alkyl-CO-C₀-2alkyl-, -C₀-2alkyl-NR¹⁰CO-C₀-2alkyl-, -C₀-2alkyl-NR¹⁰SO₂-C₀-2alkyl- or -heteroC₀-4alkyl;

25 R⁹ and R¹⁰ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

30 Z is -C₃-7cycloalkyl, -heteroC₃-7cycloalkyl, -C₀-6alkylaryl, or -C₀-6alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

R¹¹ and R¹² is each independently halogen, -C₀-6alkyl, -C₀-6alkoxyl, =O, =N(C₀-4alkyl), or -N(C₀-4alkyl)(C₀-4alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

In a fifth aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

X is aryl or heteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R²

10 substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups;

15 R¹, R², and R³ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

20 R⁴ is -C₁₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

25 A is -C₀₋₄alkyl, -C₀₋₂alkyl-SO-C₀₋₂alkyl-, -C₀₋₂alkyl-SO₂-C₀₋₂alkyl-, -C₀₋₂alkyl-CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR⁹CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR⁹SO₂-C₀₋₂alkyl- or -heteroC₀₋₄alkyl;

30 W is -C₃₋₇cycloalkyl, -heteroC₃₋₇cycloalkyl, -C₀₋₆alkylaryl, or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

35 Y is aryl or heteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or

heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups;

5 R⁵, R⁶, and R⁷ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

10 R⁸ is -C₁₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

15 B is -C₀₋₄alkyl, -C₀₋₂alkyl-SO-C₀₋₂alkyl-, -C₀₋₂alkyl-SO₂-C₀₋₂alkyl-, -C₀₋₂alkyl-CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR¹⁰CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR¹⁰SO₂-C₀₋₂alkyl- or -heteroC₀₋₄alkyl;

20 R⁹ and R¹⁰ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

25 Z is -C₀₋₆alkylaryl or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

30 R¹¹ and R¹² is each independently halogen, -C₀₋₆alkyl, -C₀₋₆alkoxyl, =O, =N(C₀₋₄alkyl), or -N(C₀₋₄alkyl)(C₀₋₄alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

In a sixth aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

35 X is aryl or heteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or

heterocycloalkyl ring fused to X; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

5 R₁, R₂, and R₃ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

10 R₄ is -C₁-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;
A is -C₀-4alkyl, -C₀-2alkyl-SO-C₀-2alkyl-, -C₀-2alkyl-SO₂-C₀-2alkyl-, -C₀-2alkyl-CO-C₀-2alkyl-, -C₀-2alkyl-NR⁹CO-C₀-2alkyl-, -C₀-2alkyl-NR⁹SO₂-C₀-2alkyl- or -heteroC₀-4alkyl;

15 W is -C₀-6alkylaryl or -C₀-6alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

20 Y is aryl or heteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

25 R₅, R₆, and R₇ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

30 R₈ is -C₁-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

35

B is $-C_0-4alkyl$, $-C_0-2alkyl-SO-C_0-2alkyl-$, $-C_0-2alkyl-SO_2-C_0-2alkyl-$, $-C_0-2alkyl-CO-C_0-2alkyl-$, $-C_0-2alkyl-NR^{10}CO-C_0-2alkyl-$, $-C_0-2alkyl-NR^{10}SO_2-C_0-2alkyl-$ or $-heteroC_0-4alkyl$;

5 R⁹ and R¹⁰ each independently is $-C_0-6alkyl$, $-C_3-7cycloalkyl$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

10 Z is $-C_3-7cycloalkyl$, $-heteroC_3-7cycloalkyl$, $-C_0-6alkylaryl$, or $-C_0-6alkylheteroaryl$ optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

15 R¹¹ and R¹² is each independently halogen, -C₀-6alkyl, -C₀-6alkoxyl, =O, =N(C₀-4alkyl), or -N(C₀-4alkyl)(C₀-4alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

In a second embodiment of the first aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

20 X is 2-pyridyl optionally substituted with 1-4 independent halogen, -CN, NO₂, -C₁-6alkyl, -C₁-6alkenyl, -C₁-6alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁-6alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), or -N(C₀-6alkyl)(aryl) groups;

30 R¹, R², and R³ each independently is -C₀-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

35 R⁴ is -C₁-6alkyl, -C₃-7cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁-6alkyl, -O(C₀-6alkyl), -O(C₃-7cycloalkyl), -O(aryl), -N(C₀-6alkyl)(C₀-6alkyl), -N(C₀-6alkyl)(C₃-7cycloalkyl), -N(C₀-6alkyl)(aryl) substituents;

A is $-C_0\text{-}4\text{alkyl}$, $-C_0\text{-}2\text{alkyl}-SO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-SO_2-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^9CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^9SO_2-C_0\text{-}2\text{alkyl}-$ or $-heteroC_0\text{-}4\text{alkyl}$;

W is $-C_0\text{-}6\text{cycloalkyl}$ or $-C_0\text{-}6\text{heterocycloalkyl}$, $-C_0\text{-}6\text{alkylaryl}$ or $-C_0\text{-}6\text{alkylheteroaryl}$ optionally substituted with 1-7 independent halogen, $-CN$, NO_2 , $-C_1\text{-}6\text{alkyl}$,

5 $-C_1\text{-}6\text{alkenyl}$, $-C_1\text{-}6\text{alkynyl}$, $-OR^1$, $-NR^1R^2$, $-C(=NR^1)NR^2R^3$, $-N(=NR^1)NR^2R^3$, $-NR^1COR^2$, $-NR^1CO_2R^2$, $-NR^1SO_2R^4$, $-NR^1CONR^2R^3$, $-SR^4$, $-SOR^4$, $-SO_2R^4$, $-SO_2NR^1R^2$, $-COR^1$, $-CO_2R^1$, $-CONR^1R^2$, $-C(=NR^1)R^2$, or $-C(=NOR^1)R^2$ substituents;

10 Y is phenyl optionally substituted with 1-5 independent halogen, $-CN$, NO_2 , $-C_1\text{-}6\text{alkyl}$, $-C_1\text{-}6\text{alkenyl}$, $-C_1\text{-}6\text{alkynyl}$, $-OR^5$, $-NR^5R^6$, $-C(=NR^5)NR^6R^7$, $-N(=NR^5)NR^6R^7$, $-NR^5COR^6$, $-NR^5CO_2R^6$, $-NR^5SO_2R^8$, $-NR^5CONR^6R^7$, $-SR^8$, $-SOR^8$, $-SO_2R^8$, $-SO_2NR^5R^6$, $-COR^5$, $-CO_2R^5$, $-CONR^5R^6$, $-C(=NR^5)R^6$, or $-C(=NOR^5)R^6$ substituents, wherein optionally two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the $-C_1\text{-}6\text{alkyl}$ substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, $-CN$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(aryl)$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, or $-N(C_0\text{-}6\text{alkyl})(aryl)$ groups;

15 R⁵, R⁶, and R⁷ each independently is $-C_0\text{-}6\text{alkyl}$, $-C_3\text{-}7\text{cycloalkyl}$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(aryl)$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(aryl)$ substituents;

20 R⁸ is $-C_1\text{-}6\text{alkyl}$, $-C_3\text{-}7\text{cycloalkyl}$, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, $-CN$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(aryl)$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(aryl)$ substituents;

25 B is $-C_0\text{-}4\text{alkyl}$, $-C_0\text{-}2\text{alkyl}-SO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-SO_2-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^{10}CO-C_0\text{-}2\text{alkyl}-$, $-C_0\text{-}2\text{alkyl}-NR^{10}SO_2-C_0\text{-}2\text{alkyl}-$ or $-heteroC_0\text{-}4\text{alkyl}$;

30 R⁹ and R¹⁰ each independently is $-C_0\text{-}6\text{alkyl}$, $-C_3\text{-}7\text{cycloalkyl}$, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, $-CN$, $-C_1\text{-}6\text{alkyl}$, $-O(C_0\text{-}6\text{alkyl})$, $-O(C_3\text{-}7\text{cycloalkyl})$, $-O(aryl)$, $-N(C_0\text{-}6\text{alkyl})(C_0\text{-}6\text{alkyl})$, $-N(C_0\text{-}6\text{alkyl})(C_3\text{-}7\text{cycloalkyl})$, $-N(C_0\text{-}6\text{alkyl})(aryl)$ substituents;

Z is $-C_0\text{-}6\text{alkylaryl}$ or $-C_0\text{-}6\text{alkylheteroaryl}$ optionally substituted with 1-7 independent halogen, $-CN$, NO_2 , $-C_1\text{-}6\text{alkyl}$, $-C_1\text{-}6\text{alkenyl}$, $-C_1\text{-}6\text{alkynyl}$, $-OR^1$, $-NR^1R^2$, $-C(=NR^1)NR^2R^3$, $-N(=NR^1)NR^2R^3$, $-NR^1COR^2$, $-NR^1CO_2R^2$, $-NR^1SO_2R^4$, $-$

NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

R¹¹ and R¹² is each independently halogen, -C₀₋₆alkyl, -C₀₋₆alkoxyl, =O,

5 =N(C₀₋₄alkyl), or -N(C₀₋₄alkyl)(C₀₋₄alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

10 In a second embodiment of this second aspect, the compounds of this invention are represented by Formula (I) or a pharmaceutically acceptable salt thereof, wherein:

X is phenyl optionally substituted with 1-5 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents, wherein optionally

15 two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to X; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups;

20 R¹, R², and R³ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

25 R⁴ is -C₁₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

A is -C₀₋₄alkyl, -C₀₋₂alkyl-SO-C₀₋₂alkyl-, -C₀₋₂alkyl-SO₂-C₀₋₂alkyl-, -C₀₋₂alkyl-CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR⁹CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR⁹SO₂-C₀₋₂alkyl- or -heteroC₀₋₄alkyl;

30 W is -C₀₋₆alkylaryl or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

Y is 2-pyridyl optionally substituted with 1-4 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR⁵, -NR⁵R⁶, -C(=NR⁵)NR⁶R⁷, -N(=NR⁵)NR⁶R⁷, -NR⁵COR⁶, -NR⁵CO₂R⁶, -NR⁵SO₂R⁸, -NR⁵CONR⁶R⁷, -SR⁸, -SOR⁸, -SO₂R⁸, -SO₂NR⁵R⁶, -COR⁵, -CO₂R⁵, -CONR⁵R⁶, -C(=NR⁵)R⁶, or -C(=NOR⁵)R⁶ substituents, wherein optionally

5 two substituents are combined to form a cycloalkyl or heterocycloalkyl ring fused to Y; wherein the -C₁₋₆alkyl substituent, cycloalkyl ring, or heterocycloalkyl ring each optionally is further substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), or -N(C₀₋₆alkyl)(aryl) groups;

10 R⁵, R⁶, and R⁷ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

15 R⁸ is -C₁₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

B is -C₀₋₄alkyl, -C₀₋₂alkyl-SO-C₀₋₂alkyl-, -C₀₋₂alkyl-SO₂-C₀₋₂alkyl-, -C₀₋₂alkyl-CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR¹⁰CO-C₀₋₂alkyl-, -C₀₋₂alkyl-NR¹⁰SO₂-C₀₋₂alkyl- or -heteroC₀₋₄alkyl;

20 R⁹ and R¹⁰ each independently is -C₀₋₆alkyl, -C₃₋₇cycloalkyl, heteroaryl, or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, -C₁₋₆alkyl, -O(C₀₋₆alkyl), -O(C₃₋₇cycloalkyl), -O(aryl), -N(C₀₋₆alkyl)(C₀₋₆alkyl), -N(C₀₋₆alkyl)(C₃₋₇cycloalkyl), -N(C₀₋₆alkyl)(aryl) substituents;

25 Z is -C₃₋₇cycloalkyl, -heteroC₃₋₇cycloalkyl, -C₀₋₆alkylaryl, or -C₀₋₆alkylheteroaryl optionally substituted with 1-7 independent halogen, -CN, NO₂, -C₁₋₆alkyl, -C₁₋₆alkenyl, -C₁₋₆alkynyl, -OR¹, -NR¹R², -C(=NR¹)NR²R³, -N(=NR¹)NR²R³, -NR¹COR², -NR¹CO₂R², -NR¹SO₂R⁴, -NR¹CONR²R³, -SR⁴, -SOR⁴, -SO₂R⁴, -SO₂NR¹R², -COR¹, -CO₂R¹, -CONR¹R², -C(=NR¹)R², or -C(=NOR¹)R² substituents;

one of W and Z is optionally absent;

30 R¹¹ and R¹² is each independently halogen, -C₀₋₆alkyl, -C₀₋₆alkoxyl, =O, =N(C₀₋₄alkyl), or -N(C₀₋₄alkyl)(C₀₋₄alkyl); and

any alkyl optionally substituted with 1-5 independent halogen substituents, and any N may be an N-oxide.

As used herein, "alkyl" as well as other groups having the prefix "alk" such as, for example, alkoxy, alkanoyl, alkenyl, alkynyl and the like, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl and the like. "Alkenyl", "alkynyl" and other like terms include carbon chains containing at least one unsaturated C-C bond.

The term "cycloalkyl" means carbocycles containing no heteroatoms, and includes mono-, bi- and tricyclic saturated carbocycles, as well as fused ring systems. Such fused ring systems can include one ring that is partially or fully unsaturated such as a benzene ring to form fused ring systems such as benzofused carbocycles. Cycloalkyl includes such fused ring systems as spirofused ring systems. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decahydronaphthalene, adamantane, indanyl, indenyl, fluorenyl, 1,2,3,4-tetrahydronaphthalene and the like. Similarly, "cycloalkenyl" means carbocycles containing no heteroatoms and at least one non-aromatic C-C double bond, and include mono-, bi- and tricyclic partially saturated carbocycles, as well as benzofused cycloalkenes. Examples of cycloalkenyl include cyclohexenyl, indenyl, and the like.

The term "aryl" means an aromatic substituent which is a single ring or multiple rings fused together. When formed of multiple rings, at least one of the constituent rings is aromatic. The preferred aryl substituents are phenyl and naphthyl groups.

The term "cycloalkyloxy" unless specifically stated otherwise includes a cycloalkyl group connected by a short C₁-2alkyl length to the oxy connecting atom.

The term "C₀₋₆alkyl" includes alkyls containing 6, 5, 4, 3, 2, 1, or no carbon atoms. An alkyl with no carbon atoms is a hydrogen atom substituent when the alkyl is a terminal group and is a direct bond when the alkyl is a bridging group.

The term "hetero" unless specifically stated otherwise includes one or more O, S, or N atoms. For example, heterocycloalkyl and heteroaryl include ring systems that contain one or more O, S, or N atoms in the ring, including mixtures of such atoms. The hetero atoms replace ring carbon atoms. Thus, for example, a heterocycloC₅alkyl is a five-member ring containing from 4 to no carbon atoms. Examples of heteroaryls include pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, and tetrazolyl. Examples of heterocycloalkyls include azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, tetrahydrofuryl, imidolinyl, pyrrolidin-2-one, piperidin-2-one, and thiomorpholinyl.

The term "heteroC₀₋₄alkyl" means a heteroalkyl containing 3, 2, 1, or no carbon atoms. However, at least one heteroatom must be present. Thus, as an example, a heteroC₀₋₄alkyl having no carbon atoms but one N atom would be a -NH- if a bridging group and a -NH₂ if a terminal group. Analogous bridging or terminal groups are clear for an O or S heteroatom.

5 The term "amine" unless specifically stated otherwise includes primary, secondary and tertiary amines substituted with C₀₋₆alkyl.

The term "carbonyl" unless specifically stated otherwise includes a C₀₋₆alkyl substituent group when the carbonyl is terminal.

The term "halogen" includes fluorine, chlorine, bromine and iodine atoms.

10 The term "optionally substituted" is intended to include both substituted and unsubstituted. Thus, for example, optionally substituted aryl could represent a pentafluorophenyl or a phenyl ring. Further, optionally substituted multiple moieties such as, for example, alkylaryl are intended to mean that the aryl and the aryl groups are optionally substituted. If only one of the multiple moieties is optionally substituted then it will be specifically recited such as "an 15 alkylaryl, the aryl optionally substituted with halogen or hydroxyl."

Compounds described herein contain one or more double bonds and may thus give rise to cis/trans isomers as well as other conformational isomers. The present invention includes all such possible isomers as well as mixtures of such isomers.

20 Compounds described herein can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. The above Formula I is shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts thereof. 25 Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.

30 The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (Ic and Ous), ferric, ferrous, lithium, magnesium, manganese (Ic and Ous), potassium, sodium, zinc and the like salts. 35 Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts.

Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthesized substituted amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include ion exchange resins such as, for example, 5 arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and 10 the like.

When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, 15 isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or pharmaceutically acceptable salts thereof) as an active ingredient, a 20 pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. Such additional therapeutic ingredients include, for example, i) opiate agonists or antagonists, ii) calcium channel antagonists, iii) 5HT receptor agonists or antagonists iv) sodium channel antagonists, v) NMDA receptor agonists or antagonists, vi) COX-2 selective inhibitors, vii) NK1 antagonists, viii) non-steroidal anti-inflammatory drugs ("NSAID"), ix) GABA-A receptor 25 modulators, x) dopamine agonists or antagonists, xi) selective serotonin reuptake inhibitors ("SSRI") and/or selective serotonin and norepinephrine reuptake inhibitors ("SSNRI"), xii) tricyclic antidepressant drugs, xiv) norepinephrine modulators, xv) L-DOPA, xvi) buspirone, xvii) lithium, xviii) valproate, ix) neurontin (gabapentin), xx) olanzapine, xxi) nicotinic agonists or antagonists including nicotine, xxii) muscarinic agonists or antagonists, xxiii) heroin 30 substituting drugs such as methadone, levo-alpha-acetylmethadol, buprenorphine and naltrexone, and xxiv) disulfiram and acamprosate. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being

administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

5 Creams, ointments, jellies, solutions, or suspensions containing the compound of Formula I can be employed for topical use. Mouth washes and gargles are included within the scope of topical use for the purposes of this invention.

Dosage levels from about 0.01mg/kg to about 140mg/kg of body weight per day are useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, bipolar disorders, and circadian disorders, as well as being useful in the treatment of pain which are responsive to mGluR5 inhibition, or alternatively about 0.5mg to 10 about 7g per patient per day. For example, schizophrenia, anxiety, depression, and panic may be effectively treated by the administration of from about 0.01mg to 75mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 3.5g per patient per day. Pain may be effectively treated by the administration of from about 0.01mg to 125mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 5.5g per 15 patient per day. Further, it is understood that the mGluR5 inhibiting compounds of this invention can be administered at prophylactically effective dosage levels to prevent the above-recited conditions.

20 The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration to humans may conveniently contain from about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between 25 from about 1mg to about 1000mg of the active ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or 1000mg.

It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

30 In practice, the compounds represented by Formula I, or pharmaceutically acceptable salts thereof, of this invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). Thus, the 35 pharmaceutical compositions of the present invention can be presented as discrete units suitable

for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion or as a water-in-oil liquid emulsion. In addition to the common dosage forms 5 set out above, the compound represented by Formula I, or pharmaceutically acceptable salts thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and 10 intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound or a pharmaceutically acceptable salt of Formula I. The compounds of Formula I, or pharmaceutically acceptable salts thereof, can also 15 be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, 20 olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, 25 microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.

30 A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a 35 suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.

Each tablet preferably contains from about 0.1mg to about 500mg of the active ingredient and each cachet or capsule preferably containing from about 0.1mg to about 500mg of the active ingredient. Thus, a tablet, cachet, or capsule conveniently contains 0.1mg, 1mg, 5mg, 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, or 500mg of the active ingredient taken one or two

5 tablets, cachets, or capsules, once, twice, or three times daily.

Pharmaceutical compositions of the present invention suitable for parenteral administration may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils.

10 Further, a preservative can be included to prevent the detrimental growth of microorganisms.

Pharmaceutical compositions of the present invention suitable for injectable use include sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for

15 easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

20 Pharmaceutical compositions of the present invention can be in a form suitable for topical use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound represented by Formula I of this invention, or pharmaceutically acceptable salts thereof, via conventional processing methods. As an

25 example, a cream or ointment is prepared by mixing hydrophilic material and water, together with about 5 wt% to about 10 wt% of the compound, to produce a cream or ointment having a desired consistency.

Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose

30 suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in moulds.

In addition to the aforementioned carrier ingredients, the pharmaceutical formulations described above may include, as appropriate, one or more additional carrier

35 ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners,

lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound described by Formula I, or pharmaceutically acceptable salts thereof, may also be prepared in powder or liquid concentrate form.

5 The compounds and pharmaceutical compositions of this invention have been found to exhibit biological activity as mGluR5 inhibitors. Accordingly, another aspect of the invention is the treatment in mammals of, for example, schizophrenia, anxiety, depression, panic, bipolar disorders, circadian rhythm and sleep disorders, pain, Parkinson's disease, cognitive dysfunction, epilepsy, obesity, drug addiction, drug abuse and drug withdrawal – maladies that
10 are amenable to amelioration through inhibition of mGluR5 – by the administration of an effective amount of the compounds of this invention. The term "mammals" includes humans, as well as other animals such as, for example, dogs, cats, horses, pigs, and cattle. Accordingly, it is understood that the treatment of mammals other than humans is the treatment of clinical correlating afflictions to those above recited examples that are human afflictions.

15 Further, as described above, the compound of this invention can be utilized in combination with other therapeutic compounds. In particular, the combinations of the mGluR5 inhibiting compound of this invention can be advantageously used in combination with i) opiate agonists or antagonists, ii) calcium channel antagonists, iii) 5HT receptor agonists or antagonists iv) sodium channel antagonists, v) NMDA receptor agonists or antagonists, vi) COX-2 selective
20 inhibitors, vii) NK1 antagonists, viii) non-steroidal anti-inflammatory drugs ("NSAID"), ix) GABA-A receptor modulators, x) dopamine agonists or antagonists, xi) selective serotonin reuptake inhibitors ("SSRI") and/or selective serotonin and norepinephrine reuptake inhibitors ("SSNRI"), xii) tricyclic antidepressant drugs, xiii) norepinephrine modulators, xiv) L-DOPA, xv) buspirone, xvi) lithium, xvii) valproate, xviii) neurontin (gabapentin), xix) olanzapine, xx)
25 nicotinic agonists or antagonists including nicotine, xxi) muscarinic agonists or antagonists, xxii) heroin substituting drugs such as methadone, levo-alpha-acetylmethadol, buprenorphine and naltrexone, and xxiii) disulfiram and acamprosate.

30 The abbreviations used herein have the following tabulated meanings. Abbreviations not tabulated below have their meanings as commonly used unless specifically stated otherwise.

Ac	acetyl
AIBN	2,2'-azobis(isobutyronitrile)
BINAP	1,1'-bi-2-naphthol
Bn	benzyl

CAMP	cyclic adenosine-3',5'-monophosphate
DAST	(diethylamino)sulfur trifluoride
DEAD	diethyl azodicarboxylate
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DIBAL	diisobutylaluminum hydride
DMAP	4-(dimethylamino)pyridine
DMF	N,N-dimethylformamide
Dppf	1,1'-bis(diphenylphosphino)-ferrocene
EDCI	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
Et ₃ N	triethylamine
GST	glutathione transferase
HMDS	hexamethyldisilazide
LDA	lithium diisopropylamide
m-CPBA	metachloroperbenzoic acid
MMPP	monoperoxyphthalic acid
MPPM	monoperoxyphthalic acid, magnesium salt 6H ₂ O
Ms	methanesulfonyl = mesyl = SO ₂ Me
MsO	methanesulfonate = mesylate
NBS	N-bromo succinimide
NSAID	non-steroidal anti-inflammatory drug
o-Tol	ortho-tolyl
OXONE®	2KHSO ₅ •KHSO ₄ •K ₂ SO ₄
PCC	pyridinium chlorochromate
Pd ₂ (dba) ₃	Bis(dibenzylideneacetone) palladium(0)
PDC	pyridinium dichromate
PDE	Phosphodiesterase
Ph	Phenyl
Phe	Benzenediyl
PMB	para-methoxybenzyl
Pye	Pyridinediyl
r.t.	room temperature
Rac.	Racemic
SAM	aminosulfonyl or sulfonamide or SO ₂ NH ₂

SEM	2-(trimethylsilyl)ethoxymethoxy
SPA	scintillation proximity assay
TBAF	tetra-n-butylammonium fluoride
Th	2- or 3-thienyl
TFA	trifluoroacetic acid
TFAA	trifluoroacetic acid anhydride
THF	Tetrahydrofuran
Thi	Thiophenediyl
TLC	thin layer chromatography
TMS-CN	trimethylsilyl cyanide
TMSI	trimethylsilyl iodide
Tz	1H (or 2H)-tetrazol-5-yl
XANTPHOS	4,5-Bis-diphenylphosphanyl-9,9-dimethyl-9H-xanthene
C ₃ H ₅	Allyl

ALKYL GROUP ABBREVIATIONS

Me	=	Methyl
Et	=	ethyl
<i>n</i> -Pr	=	normal propyl
<i>i</i> -Pr	=	isopropyl
<i>n</i> -Bu	=	normal butyl
<i>i</i> -Bu	=	isobutyl
<i>s</i> -Bu	=	secondary butyl
<i>t</i> -Bu	=	tertiary butyl
c-Pr	=	cyclopropyl
c-Bu	=	cyclobutyl
c-Pen	=	cyclopentyl
c-Hex	=	cyclohexyl

ASSAYS DEMONSTRATING BIOLOGICAL ACTIVITY

The compounds of this invention were tested against the hmGluR5a receptor stably expressed in mouse fibroblast Ltk⁻ cells (the hmGluR5a/L38-20 cell line) and activity was detected by changes in $[Ca^{++}]_i$, measured using the fluorescent Ca^{++} -sensitive dye, fura-2. InsP assays were performed in mouse fibroblast Ltk⁻ cells (LM5a cell line) stably expressing hmGluR5a. The assays described in International Patent Publication WO 0116121 can be used.

Calcium Flux Assay

The activity of compounds was examined against the hmGluR5a receptor stably expressed in mouse fibroblast Ltk⁻ cells (the hmGluR5a/L38 cell line). See generally Daggett et al., *Neuropharmacology* 34:871-886 (1995). Receptor activity was detected by changes in intracellular calcium ($[Ca^{2+}]_i$) measured using the fluorescent calcium-sensitive dye, fura-2. The hmGluR5a/L38-20 cells were plated onto 96-well plates, and loaded with 3 μ M fura-2 for 1h. Unincorporated dye was washed from the cells, and the cell plate was transferred to a 96-channel fluorimeter (SIBIA-SAIC, La Jolla, CA) which is integrated into a fully automated plate handling and liquid delivery system. Cells were excited at 350 and 385nm with a xenon source combined with optical filters. Emitted light was collected from the sample through a dichroic mirror and a 510nm interference filter and directed into a cooled CCD camera (Princeton Instruments). Image pairs were captured approximately every 1s, and ratio images were generated after background subtraction. After a basal reading of 20s, an EC₈₀ concentration of glutamate (10 μ M) was added to the well, and the response evaluated for another 60s. The glutamate-evoked increase in $[Ca^{+}]_i$ in the presence of the screening compound was compared to the response of glutamate alone (the positive control).

Phosphatidylinositol Hydrolysis (PI) Assays

Inositolphosphate assays were performed as described by Berridge et al. [Berridge et al, *Biochem. J.* 206: 587-5950 (1982); and Nakajima et al., *J. Biol. Chem.* 267:2437-2442 (1992)] with slight modifications. Mouse fibroblast Ltk cells expressing hmGluR5 (hmGluR5/L38- 20 cells) were seeded in 24-well plates at a density of 8x10⁵cells/well. One μ Ci of [³H]-inositol (Amersham PT6-271; Arlington Heights, Ill.; specific activity = 17.7 Ci/mmol) was added to each well and incubated for 16h at 37°C. Cells were washed twice and incubated for 45min in 0.5mL of standard Hepes buffered saline buffer (HBS; 125mM NaCl, 5mM KCl, 0.62mM MgSO₄, 1.8mM CaCl₂, 20mM HEPES, 6mM glucose, pH to 7.4). The cells were washed with HBS containing 10mM LiCl, and 400 μ L buffer added to each well. Cells were incubated at 37°C for 20min. For testing, 50 μ L of 10X compounds used in the practice of the invention (made in HBS/LiCl (100mM)) was added and incubated for 10 minutes. Cells were

activated by the addition of 10 μ M glutamate, and the plates left for 1 hour at 37°C. The incubations were terminated by the addition of 1mL ice-cold methanol to each well. In order to isolate inositol phosphates (IPs), the cells were scraped from wells, and placed in numbered glass test tubes. One mL of chloroform was added to each tube, the tubes were mixed, and the phases

5 separated by centrifugation. IPs were separated on Dowex anion exchange columns (AG 1-X8 100-200 mesh formate form). The upper aqueous layer (750 μ L) was added to the Dowex columns, and the columns eluted with 3mL of distilled water. The eluents were discarded, and the columns were washed with 10mLs of 60mM ammonium formate/5mM Borax, which was also discarded as waste. Finally, the columns were eluted with 4mL of 800mM ammonium

10 formate/0.1M formic acid, and the samples collected in scintillation vials. Scintillant was added to each vial, and the vials shaken, and counted in a scintillation counter after 2 hours.

Phosphatidylinositol hydrolysis in cells treated with certain exemplary compounds was compared to phosphatidylinositol hydrolysis in cells treated with the agonist alone in the absence of compound.

15 The compounds of this application have mGluR5 inhibitory activity as shown by IC₅₀ values of less than 10 μ M in the calcium flux assay or inhibition at a concentration of 100 μ M in the PI assay. Preferably, the compounds should have IC₅₀ values of less than 1 μ M in the calcium flux assay and IC₅₀ values of less than 10 μ M in the PI assay. Even more preferably, the compounds should have IC₅₀ values of less than 500 nM in the calcium flux assay and IC₅₀ values 20 of less than 1 μ M in the PI assay

Examples 1 to 6 have mGluR5 inhibitory activity as shown by inhibition at 10 μ M or less in the calcium flux assay or inhibition at 100 μ M or less in the PI assay.

The examples that follow are intended as an illustration of certain preferred embodiments of the invention and no limitation of the invention is implied.

25 Unless specifically stated otherwise, the experimental procedures were performed under the following conditions. All operations were carried out at room or ambient temperature - that is, at a temperature in the range of 18-25°C. Evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000pascals: 4.5-30mm. Hg) with a bath temperature of up to 60°C. The course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only. The structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data. When given, yields are for illustration only. When given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as 30 internal standard, determined at 300MHz, 400MHz or 500MHz using the indicated solvent.

35

Conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc. In addition, "Ar" signifies an aromatic signal. Chemical symbols have their usual meanings; the following abbreviations are used: v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).

5


Methods of Synthesis

Compounds of the present invention can be prepared according to the following 10 methods. The substituents are the same as in Formula (I) except where defined otherwise, or apparent to one in the art.

In accordance with another embodiment of the present invention, there are 15 provided methods for the preparation of heteroaryl-substituted imidazole compounds as described above. For example, many of the heterocyclic compounds described above can be prepared using synthetic chemistry techniques well known in the art (see *Comprehensive Heterocyclic Chemistry*, Katritzky, A. R. and Rees, C. W. eds., Pergamon Press, Oxford, 1984) from a heteroaryl-substituted imidazole of Formula (I).

In Schemes 1 to 5 below, X and Y are as defined above. Other variables are understood by one in the art by the context in which they are used.

20 **Scheme 1**



Thus in **Scheme 1**, a suitably substituted imidazole containing a functional group A, which is capable of undergoing a metal-catalyzed cross-coupling reaction, such as a halogen or trifluoromethanesulfonate and the like (prepared using synthetic chemistry techniques well 25 known in the art) may be coupled with a species X substituted with a group B. B may be a metalloid such as $\text{B}(\text{OR})_2$, BiLn or related species and the reaction may be promoted with stoichiometric or catalytic amounts of metal salts such as $\text{Cu}(\text{OAc})_2$, CuI , $[\text{Cu}(\text{OH})\text{TMEDA}]_2\text{Cl}_2$ or CuOTf and the like. Typically a base (e.g. pyridine, NEt_3 , Cs_2CO_3 , K_3PO_4 , K_2CO_3 etc.) will also be present and the reaction carried out in a suitable solvent (e.g. DCM, THF, DME, dioxane, 30 toluene, MeCN , DMF, H_2O etc.). Additionally, molecular sieves may be used as a cocatalyst and an atmosphere of oxygen may be required. The cross-coupling reaction may be carried out at rt

or heated to a temperature between about 30°C to 150°C. The reaction mixture is then maintained at a suitable temperature for a time in the range of about 4 up to 72h, with 18h typically being sufficient (see for example Lam, P. Y. S.; Clark, C. G.; Saubern, S.; Adams, J.; Winters, M. P.; Cham, D. M. T.; Combs, A. *Tetrahedron Lett.* **1998**, *39*, 2941-2944 and


5 Kiyomori, A.; Marcoux, J. F.; Buchwald, S. L. *Tetrahedron Lett.* **1999**, *40*, 2657-2660 and Collman, J.P.; Zhong, M. *Org. Lett.* **2000**, *2*, 9, 1233-1236). The product from the reaction can be isolated and purified employing standard techniques, such as solvent extraction, chromatography, crystallization, distillation and the like.

In another embodiment of the present invention when **B** is a good leaving group such as F, and **X** is electron deficient or has one or more electron withdrawing substituents (e.g. NO₂, CN), the coupling reaction may be effected thermally in a temperature range of about 60°C up to about 250°C. Typically, this reaction is carried out in the presence of base (e.g. pyridine, NEt₃, Cs₂CO₃, K₂CO₃ etc.) in a suitable solvent, such as DMSO, DMF, DMA H₂O and the like, and takes from 1h up to about 72h with 18h typically being sufficient (see for example Davey, D. 15 D.; Erhardt, P. W.; Cantor, E. H.; Greenberg, S. S.; Ingebretsen, W. R.; Wiggins; *J.Med.Chem.* **1991**, *34*, 9, 2671-2677).

In turn the derivatized imidazole is reacted with a moiety **Y** under metal-catalyzed cross-coupling conditions (Scheme 2)

20

Scheme 2




where **E** is a metallic or metalloid species such as B(OR)₂, Li, MgHal, SnR₃, ZnHal, SiR₃ and the like which is capable of undergoing a metal-catalyzed cross-coupling reaction. The coupling may be promoted by a homogeneous catalyst such as Pd(PPh₃)₄, or by a heterogeneous catalyst such as Pd on carbon in a suitable solvent (e.g. THF, DME, toluene, MeCN, DMF, H₂O etc.). Typically a base, such as K₂CO₃, NEt₃, and the like, will also be present in the reaction mixture. Other promoters may also be used such as CsF. The reaction mixture is maintained at rt, or 25 heated to a temperature between 30°C to 150°C. The reaction mixture is then maintained at a suitable temperature for a time in the range of about 4 up to 48h, with about 18h typically being sufficient (see for example Miyaura, N.; Suzuki, A. *Chem. Rev.* **1995**, *95*, 2457-2483). The

30

product from the reaction can be isolated and purified employing standard techniques, such as solvent extraction, chromatography, crystallization, distillation and the like.

Another embodiment of the present invention is illustrated in **Scheme 3**:

Scheme 3



Thus a suitably substituted imidazole containing a functional group A, which is capable of undergoing a metal-catalyzed cross-coupling reaction, such as a halogen or trifluoromethanesulfonate and the like (prepared using synthetic chemistry techniques well known in the art) may be coupled with a species Y substituted with a group E where E is a


10 metallic or metalloid species such as $B(OR)_2$, Li, MgHal, SnR_3 , $ZnHal$, SiR_3 and the like. The coupling may be promoted by a homogeneous catalyst such as $Pd(PPh_3)_4$, or by a heterogeneous catalyst such as Pd on carbon in a suitable solvent (e.g. THF, DME, toluene, MeCN, DMF, H_2O etc.). Typically a base, such as K_2CO_3 , NEt_3 , and the like, will also be present in the reaction mixture. Other promoters may also be used such as CsF. The reaction mixture is maintained at

15 rt, or heated to a temperature between about 30°C to 150°C. The reaction mixture is then maintained at a suitable temperature for a time in the range of about 4h up to 48h, with about 18h typically being sufficient (see for example Miyaura, N.; Suzuki, A. *Chem. Rev.* 1995, 95, 2457-2483 or Negishi, E., Liu, F., Palladium or Nickel catalyzed Cross-coupling with Organometals Containing Zinc, Magnesium, Aluminium and Zirconium in *Metal-catalyzed Cross-coupling Reactions* Diederich, F.; Stang, P.J. Eds. Wiley, Weinheim, Germany, 1998; pp1-42).

20 The product from the reaction can be isolated and purified employing standard techniques, such as solvent extraction, chromatography, crystallization, distillation and the like.

Another embodiment of the present invention is illustrated in **Scheme 4**:

Scheme 4




Thus a suitably substituted species Y containing a pendant aldehyde group (prepared using synthetic chemistry techniques well known in the art) may be converted to a substituted imidazole in a two step procedure. First, the aldehyde is converted to an intermediate

substituted oxazole using tosylmethylisocyanide in a suitable solvent (e.g. THF, EtOH, dioxane, DCM, toluene *etc.*) in the presence of a suitable base (such as NaH, KOtBu, KCN, K₂CO₃ *etc.*). The reaction mixture is then maintained at rt, or heated to a temperature between about 30°C to 100°C. The reaction mixture is then maintained at the required temperature for a time in the 5 range of about 2h up to 48h, with about 6h typically being sufficient. The intermediate oxazole is then heated with ammonia in a suitable solvent (e.g. THF, MeOH, DCM, toluene, dioxane *etc.*). The reaction mixture is then maintained at ambient temperature, or heated to a temperature anywhere between 30°C to 150°C. The reaction mixture is then stirred for a time in the range of about 2 up to 48h, with about 24h typically being sufficient. The product from the reaction can 10 be isolated and purified employing standard techniques, such as solvent extraction, chromatography, crystallization, distillation and the like (see for example Wang, F.; Schwabacher, A. W. *Tetrahedron Lett.* 1999, 40, 4779-4782).

As shown in **Scheme 5**, the imidazole may then be coupled with a ring system X substituted with a functional group B.

15 **Scheme 5**



B may be a metalloid species such as B(OR)₂, BiLn or the like and the reaction may be promoted with stoichiometric or catalytic amounts of metal salts such as Cu(OAc)₂, CuI, [Cu(OH)TMEDA]₂Cl₂ or CuOTf and the like. Typically, a base (e.g. pyridine, NEt₃, Cs₂CO₃, 20 K₃PO₄, K₂CO₃ *etc.*) will also be present and the reaction carried out in a suitable solvent (e.g. DCM, THF, DME, dioxane, toluene, MeCN, DMF, H₂O *etc.*). Additionally, molecular sieves may be used as a cocatalyst and an atmosphere of oxygen may be required. The cross-coupling reaction may be carried out at ambient temperature or heated to a temperature anywhere between 30°C to 150°C. The reaction mixture is then maintained at a suitable temperature for a time in 25 the range of about 4 up to 72h, with 18h typically being sufficient (see for example Lam, P. Y. S.; Clark, C. G.; Saubern, S.; Adams, J.; Winters, M. P.; Cham, D. M. T.; Combs, A. *Tetrahedron Lett.* 1998, 39, 2941-2944 and Kiyomori, A.; Marcoux, J. F.; Buchwald, S. L. *Tetrahedron Lett.* 1999, 40, 2657-2660 and Collman, J.P.; Zhong, M. *Org. Lett.* 2000, 2, 9, 1233-1236). The product from the reaction can be isolated and purified employing standard 30 techniques, such as solvent extraction, chromatography, crystallization, distillation and the like.

Alternatively, **B** may be a leaving group capable of undergoing a metal-catalyzed cross-coupling reaction such as a halogen or trifluoromethanesulfonate and the like. Typically, the reaction is carried out using catalytic amounts of a copper (I) salt together with a di-amine ligand and in the presence of a suitable base (e.g. K_3PO_4 , Cs_2CO_3 , K_2CO_3 etc.) in a suitable 5 solvent, such as dioxane, DMSO, DMA, DMF (see for example Klapars, A.; Antilla, J.C.; Huang, X.; Buchwald, S.L *J. Am. Chem. Soc.* **2001**, *123*(31); 7727-7729).


Additionally, when **B** is a good aryl leaving group such as F, and **X** is electron deficient or has one or more electron withdrawing substituents (e.g. NO_2 , CN), the coupling reaction may be effected thermally in a temperature range of about 60°C up to about 250°C.

10 Typically, this reaction is carried out in the presence of base (e.g. pyridine, NEt_3 , Cs_2CO_3 , K_2CO_3 etc.) in a suitable solvent, such as DMSO, DMF, DMA H_2O and the like, and takes from 1h up to about 72h with 18h typically being sufficient (see for example Davey, D. D.; Erhardt, P. W.; Cantor, E. H.; Greenberg, S. S.; Ingebretsen, W. R.; Wiggins; *J. Med. Chem.* **1991**, *34*, 9, 2671-2677).

15 In the schemes above, ring systems **X** and/or **Y** may already contain a pendant ring **W** and/or **Z**. However, if required, ring systems **W** and/or **Z** may be appended to **X** and/or **Y** respectively where **G** and/or **J** are functional groups capable of undergoing a metal catalyzed-cross coupling (such as halogen, trifluoromethane-sulfonate, $B(OR)_2$, ZnX , SnR_3 , and the like - 20 **Scheme 6** below). Ring systems **W** and **Z** are substituted with groups **P**, **Q**, **S** and **T** which may be for example, halogen, trifluoromethanesulfonate, $B(OR)_2$, ZnX , SnR_3 , and the like.

Typically, a transition metal catalyst such as $Pd(PPh_3)_4$, $Pd(PPh_3)_2Cl_2$, $Pd(OAc)_2$, $NiCl_2(dppe)$, $Pd(OAc)_2$, $Pd_2(dba)_3$, $Cu(OAc)_2$, CuI or the like may be employed, typically along with a suitable base such as K_2CO_3 , K_3PO_4 , Cs_2CO_3 , Et_3N , pyridine or the like. Additionally, ligands such as BINAP, di-*tert*-butyl phosphinobiphenyl, di-cyclohexylphosphino biphenyl, tri *tert*- 25 butylphosphine, XANTPHOS, triphenylarsine and the like may be added. The reaction is carried out in a suitable solvent such as toluene, DME, dioxane, THF, water or a combination of the above and is typically heated at 50°C – 150°C for between 1 and 48 hrs. The reaction may be homogeneous or heterogeneous (see for example Miyaura, N.; Suzuki, A. *Chem. Rev.* **1995**, *95*, 2457-2483 and Dai, C.; Fu, G.C *J. Am. Chem. Soc.*, **2001**, *123*, 2719-2724 and Little, A.F.; Fu, 30 G.C. *Angew. Chem. Int. Ed.* **1999**, *38*, 6, 2411-2413 and Dai, C; Fu, G.C. *J. Am. Chem. Soc.* **2001**, *123*, 2719-2724).

Scheme 6



Alternatively ring systems W or Z may be a nitrogen containing heterocycle wherein the nitrogen is directly attached to the ring system X or Y respectively. In this case G and/or J are groups capable of undergoing a metal catalyzed N-aryl cross-coupling (such as halogen, trifluoromethane-sulfonate, $B(OR)_2$, ZnX , SnR_3 , and the like – **Scheme 6**). Typically a transition metal such as CuI , $Cu(OAc)_2$, $Cu(OTf)_2$, $Pd(PPh_3)_4$, $Pd(PPh_3)_2Cl_2$, $Pd(OAc)_2$, $Pd_2(dba)_3$, $NiCl_2(dppe)$ is used along with a suitable base such as K_2CO_3 , K_3PO_4 , Cs_2CO_3 , $NaOtBu$ or the like. Additionally, phosphine containing ligands such as BINAP, di-*tert*-butyl phosphinobiphenyl, di-cyclohexylphosphino biphenyl, tri *tert*-butylphosphine, XANTPHOS and the like may be added. Further, additives such as 1,10-phenanthroline, 1,2-diaminocyclohexane, dibenzylideneacetone may be used. The reaction is typically carried out in a solvent such as toluene, DME, dioxane, THF, water or a combination of the above and is typically heated at 50°C – 150°C for between 1 and 48 hrs. The reaction may be homogeneous or heterogeneous. The product from **Scheme 6**, can be isolated and purified employing standard techniques, such as

solvent extraction, acid-base extraction, chromatography, crystallization, distillation and the like (see for example Lam, P. Y. S.; Clark, C. G.; Saubern, S.; Adams, J.; Winters, M. P.; Cham, D. M. T.; Combs, A. *Tetrahedron Lett.* **1998**, *39*, 2941-2944 and Kiyomori, A.; Marcoux, J. F.; Buchwald, S. L. *Tetrahedron Lett.* **1999**, *40*, 2657-2660 and Wolfe, J.P.; Tomori, H.; Sadighi, 5 J.P.; Yin, J.; Buchwald, S.L. *J. Org. Chem.*, **2000**, *65*, 1158-1174 and Yin, J.; Buchwald, S.L.; *Org. Lett.*, **2000**, *2*, 1101-1104).

In addition, many of the heterocyclic compounds described above can be prepared using other synthetic chemistry techniques well known in the art (see *Comprehensive* 10 *Heterocyclic Chemistry*, Katritzky, A. R. and Rees, C. W. eds., Pergamon Press, Oxford, 1984) and references cited there within.

COMPOUND 1

15 Synthesis of 4-(4-bromophenyl)-1*H*-imidazole

A solution of 4-bromophenylacetyl bromide (2.5 g, 9 mmol) in formamide (45 mL) was heated to 190° C for 2 h. The reaction mixture was allowed to cool to room temperature and then poured into water (200 mL). The resulting mixture was extracted with dichloromethane (100 mL) and washed with water and brine. The organic layer was dried over Na₂SO₄, filtered, 20 and concentrated *in vacuo*. ¹H-NMR (CD₃OD, 500 MHz): δ 7.75 (s, 1H), 7.66-7.64 (m, 2H), 7.53-7.49 (m, 3H).

COMPOUND 2

Synthesis of 2-[4-(4-bromophenyl)-1*H*-imidazol-1-yl]pyridine

To a solution of compound 1 (0.9 g, 4.0 mmol) in DMF (4.0 mL) was added 2- 25 bromopyridine (0.4 mL, 4.0 mmol) and potassium carbonate (1.7 g, 12.0 mmol). The resulting suspension was heated to 170-180° C for 12 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (100 mL), and washed with water and brine. The organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude residue was purified 30 by silica gel chromatography, eluting with 50-80% EtOAc/hexane, to afford 2-[4-(4-bromophenyl)-1*H*-imidazol-1-yl]pyridine as brown solid. ¹H-NMR (CDCl₃, 500 MHz): δ 8.54-8.53 (d, 1H), 8.39 (s, 1H), 7.99 (s, 1H), 7.90-7.87 (m, 1H), 7.77-7.76 (m, 2H), 7.56-7.55 (m, 2H), 7.45-7.43 (m, 1H), 7.31-7.38 (m, 1H). MS (ESI) 300.0 (M⁺).

EXAMPLE 1

35 Synthesis of 2-[4-(4-pyridin-3-ylphenyl)-1*H*-imidazol-1-yl]pyridine

To a solution of compound 2 (580 mg, 1.9 mmol) in dioxane (12.8 mL) was added pyridine-3-boronic acid (470 mg, 3.8 mmol), potassium phosphate (810 mg, 3.8 mmol), palladium acetate (43 mg, 0.2 mmol), and 1,1'-bis(diphenylphosphino)ferrocene (160 mg, 0.3 mmol). The reaction flask was sealed and the reaction mixture was heated to 110° C for 12 h.

5 The reaction mixture was allowed to cool to room temperature and then quenched by dilution with EtOAc (100 mL) and filtered over a cake of Celite. The filtrate was washed with water and brine, dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography, eluting with 0-10% MeOH/EtOAc, to afford 2-[4-(4-pyridin-3-ylphenyl)-1*H*-imidazol-1-yl]pyridine. ¹H-NMR (CD₃OD, 500 MHz): 8.83 (s, 1H), 8.60 (s, 1H), 8.51-8.50 (d, 2H), 8.29 (s, 1H), 8.10 (m, 1H), 7.97-7.93 (m, 3H), 7.74-7.69 (m, 3H), 7.52-7.50 (m, 1H), 7.38-7.35 (m, 1H). MS 299.1 (M⁺ + H).

10

COMPOUND 3
Synthesis of 2-(1*H*-imidazol-4-yl)pyridine

15 2-(1*H*-Imidazol-4-yl)pyridine was prepared according to the method of Wang, F.; Schwabacher, A. W. *Tetrahedron Lett.* 1999, 40, 4779-4782.

COMPOUND 4
Synthesis of 2-[1-(3-bromo-5-methylphenyl)-1*H*-imidazol-4-yl]pyridine

20 To a solution of compound 3 (1.4 g, 9.5 mmol) in DMF (4.8 mL) was added 3,5-dibromotoluene (3.8 g, 15.2 mmol), copper iodide (181 mg, 1.0 mmol), 1,10-phenanthroline (343 mg, 1.9 mmol), and cesium carbonate (6.5 g, 20 mmol). The resulting mixture was heated to 110° C for 16 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (100 mL) and filtered over a cake of Celite. The filtrate was washed with water and brine. The organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography, eluting with 50% MeOH/EtOAc, to afford 2-[1-(3-bromo-5-methylphenyl)-1*H*-imidazol-4-yl]pyridine. ¹H-NMR (CDCl₃, 500 MHz): δ 8.60-8.59 (m, 1H), 8.06-8.03 (m, 2H), 7.91 (s, 1H), 7.80-7.77 (m, 1H), 7.48 (s, 1H), 7.38 (s, 1H), 7.22 (s, 1H), 7.21-7.20 (m, 1H). MS (ESI) 314.1 (M⁺).

25

30

EXAMPLE 2




Synthesis of 2-[1-(3-methyl-5-pyridin-3-ylphenyl)-1*H*-imidazol-4-yl]pyridine


35 Compound 4 (0.36 g, 1.2 mmol), pyridine-3-boronic acid (281 mg, 2.3 mmol), potassium phosphate (486 mg, 2.3 mmol), palladium acetate (27 mg, 0.1 mmol), and dppf (94 mg, 0.2 mmol) were combined in dioxane (7.7 mL) and heated to 110° C for 48 h. The reaction

5 mixture was allowed to cool to room temperature, diluted with EtOAc (100mL) and filtered over a cake of Celite. The filtrate was washed with water and brine. The organic layer was dried over Na₂SO₄, filtered, and concentrated *in vacuo*. The crude residue was purified by silica gel chromatography, eluting with 50-80% MeOH/EtOAc, to afford 2-[1-(3-methyl-5-pyridin-3-ylphenyl)-1H-imidazol-4-yl]pyridine. ¹H-NMR (CD₃OD, 500 MHz): 8.92-8.91 (d, 1H), 8.66-8.65 (m, 1H), 8.60-8.58 (m, 1H), 8.41 (m, 2H), 8.23-8.21 (m, 1H), 8.00-7.94 (m, 2H), 7.76 (s, 1H), 7.62-7.57 (m, 3H), 7.37 (m, 1H), 2.56 (s, 3H). MS: 313.1 (M⁺ + H).

10

EXAMPLE 3 to EXAMPLE 6 shown below were prepared similarly to the schemes and procedures described above.

EXAMPLE	Structure	¹ H NMR	MS (ESI)
3		8.92-8.90 (m, 1H), 8.67 (s, 1H), 8.56-8.55 (m, 1H), 8.47 (s, 1H), 8.22 (m, 1H), 8.11 (s, 1H), 8.04-8.01 (m, 1H), 7.96-7.91 (d, 1H), 7.88-7.87 (d, 1H), 7.82-7.80 (d, 1H), 7.75-7.74 (m, 1H), 7.71-7.68 (m, 1H), 7.58- 7.56 (m, 1H), 7.44-7.41 (m, 1H), 6.85-6.84 (d, 1H).	MS 338.1(M+ H) ⁺ .
4		8.99 (s, 1H), 8.68 (s, 1H), 8.66 (s, 1H), 8.62-8.61 (m, 1H), 8.56-8.55 (m, 1H), 8.25 (s, 1H), 8.18-8.16 (m, 1H), 8.09-8.06 (m, 1H), 7.98-7.96 (m, 1H), 7.89-7.88 (m, 1H), 7.65- 7.63 (m, 1H), 7.57-7.51 (m, 2H), 7.44-7.41 (m, 1H)	MS 299.1(M+ H) ⁺ .
5		9.58 (br, 1H), 8.95-8.94 (m, 1H), 8.61-8.58 (m, 1H), 8.47 (m, 1H),	MS 317.2(M+ H) ⁺ .

EXAMPLE	Structure	¹ H NMR	MS (ESI)
		8.29-8.27 (br m, 2H), 8.04-8.02 (m, 2H), 7.97-7.94 (m, 1H), 7.78-7.77 (m, 1H), 7.72-7.70 (m, 1H), 7.60-7.58 (m, 1H), 7.46-7.43 (m, 1H).	H) ⁺ .
6		8.82-8.80 (m, 2H), 8.41-8.39 (m, 1H), 8.19-8.16 (m, 1H), 8.14-8.13 (d, 1H), 7.84-7.83 (m, 1H), 7.75-7.72 (m, 1H), 7.63-7.62 (m, 1H), 7.56-7.44 (m, 5H).	MS 337.2 (M+H) ⁺ .

Other variations or modifications, which will be obvious to those skilled in the art, are within the scope and teachings of this invention. This invention is not to be limited except as set forth in the following claims.